Summary
Precision drug development is focusing on targeting tumor cell surface proteins for therapeutic delivery, maximizing biomarker identified on-target damage to the tumor while minimizing toxicity. A recent article demonstrated high expression of B7-H4 antigen on resistant ovarian cancer cells and described preclinical activity of B7-H4–directed antibody–drug conjugate.
©2024 American Association for Cancer Research
2024
American Association for Cancer Research
You do not currently have access to this content.